Crossmark

Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda

Crossref DOI link: https://doi.org/10.1186/s12879-017-2680-6

Published Online: 2017-08-22

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ssempijja, Victor https://orcid.org/0000-0003-2609-6525
Nakigozi, Gertrude

Chang, Larry

Gray, Ron

Wawer, Maria

Ndyanabo, Anthony

Kasule, Jingo

Serwadda, David

Castelnuovo, Barbara

Hoog, Anja van’t

Reynolds, Steven James
Funding

Funding for this research was provided by:

National Cancer Institute (HHSN261200800001E)

National Institute of Allergy and Infectious Diseases (D43TW009771, AI001040)
License Information

Text and Data Mining valid from 2017-08-22

Version of Record valid from 2017-08-22
More Information

Article History

Received: 23 April 2017

Accepted: 13 August 2017

First Online: 22 August 2017

Ethics approval and consent to participate

: The retrospective use of de-identified, routinely collected clinical data was approved by the Uganda Virus Research Institute’s Research and Ethics Committee, The Institutional Review Board for Johns Hopkins University School of Medicine, and the Uganda National Council for Science and Technology. Individual informed consent was not obtained.

: Not applicable.

: BC is a member of the editorial board for the BMC Infectious Diseases journal. Other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below